Brilliant Violet 421™ anti-human CD279 (PD-1) Antibody

Product Details

Verified Reactivity

Human

Reported Reactivity

African Green, Baboon, Chimpanzee, Common Marmoset, Cynomolgus, Rhesus, Squirrel Monkey

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation

The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 421™ under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Brilliant Violet 421™ excites at 405 nm and emits at 421 nm. The standard bandpass filter 450/50 nm is recommended for detection. Brilliant Violet 421™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

Excitation Laser

Violet Laser (405 nm)

Application Notes

Additional reported applications (for the relevant formats) include: blocking of ligand binding^1-3, immunohistochemical staining of paraformaldehyde fixed frozen sections¹³, and spatial biology (IBEX)^15,16. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 329911 and 329912). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 329926) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)

1. Dorfman DM, et al. 2006 Am. J. Surg. Pathol. 30:802. (FA)
2. Radziewicz H, et al. 2007. J. Virol. 81:2545. (FA)
3. Velu V, et al. 2007. J. Virol. 81:5819. (FA)
4. Zahn RC, et al. 2008. J. Virol. 82:11577. PubMed
5. Chang WS, et al. 2008. J. Immunol. 181:6707. (FC) PubMed
6. Nakamoto N, et al. 2009. PLoS Pathog. 5:e1000313. (FA)
7. Jones RB, et al. 2009. J. Virol. 83:8722. (FC) PubMed
8. Vojnov L, et al. 2010. J. Virol. 84:753. (FC) PubMed
9. Radziewicz H, et al. 2010. J. Immunol. 184:2410. (FC) PubMed
10. Monteriro P, et al. 2011. J. Immunol. 186:4618. PubMed
11. Conrad J, et al. 2011. J. Immunol. 186:6871. PubMed
12. Salisch NC, et al. 2010. J. Immunol. 184:476. (Rhesus reactivity)
13. Li H and Pauza CD. 2015. Eur. J. Immunol. 45:298. (IHC)
14. Peterson VM, et al. 2017. Nat. Biotechnol. 35:936. (PG)
15. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
16. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

Product Citations

1. Kim JH, et al. 2020. Sci Rep. 10:1835. PubMed
2. Jiang W, et al. 2021. Sci Rep. 11:1864. PubMed
3. Wei H, et al. 2022. Front Immunol. 13:1060695. PubMed
4. Touizer E, et al. 2023. iScience. 26:105862. PubMed
5. Wang P, et al. 2023. Front Immunol. 13:1104329. PubMed
6. Statzu M, et al. 2023. Nat Microbiol. 8:299. PubMed
7. Giles JR, et al. 2022. Immunity. 55:557. PubMed
8. Jung IY, et al. 2022. Sci Transl Med. 14:eabn7336. PubMed
9. Geetha H. Mylvaganam, Daniel Rios 2017. Proc Natl Acad Sci U S A. 114(8):1976-1981. PubMed
10. Cheng DN, et al. 2023. Elife. 12:. PubMed
11. Kim HS, et al. 2023. Front Cell Infect Microbiol. 13:1101291. PubMed
12. Wang X, et al. 2023. Stem Cell Rev Rep. . PubMed
13. Komech EA, et al. 2022. Front Immunol. 13:973243. PubMed
14. Claiborne DT, et al. 2019. PLoS Pathog. 15:e1007981. PubMed
15. Whitney JB, et al. 2018. Nat Commun. 9:5429. PubMed
16. Gibellini L, et al. 2020. EMBO Mol Med. 12:e13001. PubMed
17. Mylvaganam G, et al. 2014. J Immunol. 193:4527. PubMed
18. Goncharov MM, et al. 2022. Elife. 11:. PubMed
19. Mastelic-Gavillet B, et al. 2019. J Immunother Cancer. 7:257. PubMed
20. Hagan T, et al. 2020. Cell. 178(6):1313-1328.e13.. PubMed
21. Parackova Z, et al. 2020. Sci Rep. 0.759027778. PubMed
22. Wu VH, et al. 2020. JCI Insight. 5:00. PubMed
23. Nielsen CM, et al. 2021. Cell Reports Medicine. 2(3):100207. PubMed
24. Gupta R, et al. 2022. Front Immunol. 13:886442. PubMed
25. Wang Z, et al. 2021. Cell Mol Immunol. 18:2188. PubMed
26. AC Belkina, JE Snyder-Cappione 2017. Cytometry A. 91:175-179. PubMed
27. Calascibetta F, et al. 2016. J Virol. 90: 7541 - 7551. PubMed
28. Ahmed R, et al. 2020. Cell Rep. 33:108501. PubMed
29. Massafra V, et al. 2021. J Immunol. 207:493. PubMed
30. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
31. Eberhardt K, et al. 2015. Clin Infect Dis. 61: 1615 - 1623. PubMed
32. Tauriainen J, et al. 2017. Sci Rep. 7:40354. PubMed
33. Lindesmith LC, et al. 2020. Cell Mol Gastroenterol Hepatol. 0.586805556. PubMed
34. Harper J, et al. 2022. J Clin Invest. . PubMed
35. Cui J, et al. 2020. Cancers (Basel). 0.596527778. PubMed
36. Ollé Hurtado M, et al. 2019. PLoS One. 14:e0216373. PubMed
37. Kobayashi Y, et al. 2020. Int J Oncol. 999:56. PubMed
38. Mineo M, et al. 2020. Molecular Cell. 78(6):1207-1223.e8. PubMed
39. van der Ploeg K, et al. 2022. Cell Rep Med. 3:100640. PubMed
40. Herter JM, et al. 2022. Strahlenther Onkol. Online ahead of print. PubMed
41. Minagawa A, et al. 2018. Cell Stem Cell. 1.548611111. PubMed
42. Juno JA, et al. 2020. Nat Med. 26:1428. PubMed
43. Bergamaschi L, et al. 2021. Immunity. 54(6):1257-1275.e8. PubMed
44. Kreutmair S, et al. 2021. Immunity. . PubMed
45. Kwon M, et al. 2020. Clin Cancer Res. 1644:26. PubMed
46. Xu L, et al. 2021. Front Oncol. 11:686156. PubMed
47. Naidoo KK, et al. 2020. PLoS One. 15:e0242448. PubMed
48. Li L, et al. 2020. J Transl Med. 18:363. PubMed
49. Seo IH, et al. 2021. Immune Netw. 21:e17. PubMed
50. Minassian AM, et al. 2021. Med (N Y). 2:701. PubMed
51. André P et al. 2018. Cell. 175(7):1731-1743 . PubMed
52. Sayin I, et al. 2018. J Exp Med. 7:40286. PubMed
53. Miller IC, et al. 2021. Nature Biomedical Engineering. :. PubMed
54. Lu Y, et al. 2021. Gastroenterology. 161:575. PubMed
55. El Ahanidi H, et al. 2022. Front Oncol. 11:795242. PubMed
56. Cao J, et al. 2018. Nat Commun. 9:77. PubMed
57. Lee SWL, et al. 2018. Front Immunol. 8:1064. PubMed
58. Herrera FG, et al. 2019. Int J Radiat Oncol Biol Phys. 103:320. PubMed
59. Buggert M, et al. 2014. J Immunol. 192:2099. PubMed
60. Buggert M, et al. 2014. J Immunol. 192:4685. PubMed
61. Jung JH, et al. 2021. Nat Commun. 12:4043. PubMed
62. Ferrando-Martinez S, et al. 2018. J Clin Invest. 128:2089. PubMed
63. Rutishauser L, et al. 2017. AIDS Res Hum Retroviruses . 10.1089/AID.2016.0324. PubMed
64. Pacheco Y, et al. 2013. J Immunol. 191:2072. PubMed
65. Li C, et al. 2020. Immunity. 52(1):201-202. PubMed
66. Buggert M, et al. 2020. Cell. 183(7):1946-1961.e15. PubMed
67. Zabaleta N, et al. 2021. Cell Host Microbe. :. PubMed
68. Harper JL, et al. 2020. Nat Med. 519:26. PubMed
69. Pilkinton MA, et al. 2017. Vaccine. 35:329. PubMed
70. Routhu NK, et al. 2021. Immunity. 54(3):542-556.e9. PubMed
71. Horn C, et al. 2021. HIV Med. 22:397. PubMed
72. Zebley CC, et al. 2021. Cell Rep. 37:110079. PubMed
73. Bradley T, et al. 2020. Nat Commun. 11:948. PubMed
74. Lee J, et al. 2015. Clin Immunol. 159: 37-46. PubMed
75. RY H, et al. 2016. Oncoimmunology. 6:e1249561. PubMed
76. Han Q, et al. 2020. Cell Rep. 30:1553. PubMed
77. Gannon PO, et al. 2020. Cytotherapy. 22(12):780-791. PubMed
78. de Jonge K, et al. 2021. OncoImmunology. 10(1):1873585. PubMed
79. Bhattacharya P, et al. 2020. Elife. 9:00. PubMed
80. Bengsch B et al. 2018. Immunity. 48(5):1029-1045 . PubMed
81. Leng T, et al. 2019. Cell Rep. 28:3077. PubMed
82. Levin MJ, et al. 2018. J Clin Invest. 128:4429. PubMed
83. Sade–Feldman M, et al. 2018. Cell. 175:998. PubMed
84. Baxter AE, et al. 2017. Nat Protoc. 12:2029. PubMed
85. Celis‐Gutierrez J et al. 2019. Cell Rep. 27(11):3315-3330 . PubMed
86. Collinson–Pautz MR, et al. 2019. Leukemia. 33:2195. PubMed
87. Sam J, et al. 2020. Front Oncol. 10:575737. PubMed
88. Karlsson J, et al. 2020. Nat Commun. 1.773611111. PubMed
89. Claiborne D, et al. 2015. Proc Natl Acad Sci U S A. 112:1480. PubMed
90. Riberdy JM, et al. 2020. Mol Ther Methods Clin Dev. 1.146527778. PubMed
91. Suzuki S, et al. 2020. Cancer Sci. 1943:111. PubMed
92. Guéguen P, et al. 2021. Sci Immunol. 6:. PubMed
93. Kim N, et al. 2020. Nat Commun. 2.045138889. PubMed
94. Nicholas K, et al. 2015. Cytometry A. 10.1002/cyto.a.22799. PubMed
95. Paris R, et al. 2015. PLoS One. 10: 0144767. PubMed

RRID

AB_10900818 (BioLegend Cat. No. 329919)
AB_10900818 (BioLegend Cat. No. 329920)

Antigen Details

Structure

Immunoglobulin superfamily

Distribution

Transiently expressed on CD4^- CD8^- thymocytes; upregulated in thymocytes and splenic T and B lymphocytes; expressed on activated myeloid cells

Ligand/Receptor

B7-H1 (also known as PD-L1) and B7-DC (PD-L2)

Cell Type

B cells, Lymphocytes, T cells, Thymocytes, Tregs

Biology Area

Cancer Biomarkers, Immunology, Inhibitory Molecules

Molecular Family

CD Molecules, Immune Checkpoint Receptors

Gene ID

5133 View all products for this Gene ID

Specificity (DOES NOT SHOW ON TDS):

CD279

Specificity Alt (DOES NOT SHOW ON TDS):

CD279

App Abbreviation (DOES NOT SHOW ON TDS):

FC

UniProt

View information about CD279 on UniProt.org

Documentation

• Technical data sheet
• Certificate of Analysis
• Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What is the F/P ratio range of our BV421™ format antibody reagents?

It is lot-specific. On average it ranges between 2-4.

Other Formats

Certificate of Analysis